Method for collecting data to predict risk of developing allergies
AssigneeApplied Medical Enzyme Research Institute Corporation
InventorsHiroshi Kido, Makoto Irahara, Koichi Suzuki
Life of this patent
Estimating the term…
Abstract
A means for predicting an infant's risk of developing an allergy to an allergen is provided. IgG1 antibody titers and IgE antibody titers against egg white in a sample of infants 6 months old or younger are measured using a DCP chip, and a scattergram is created by plotting the IgG1 antibody titer on an X axis and the IgE antibody titer on a Y axis. For data distribution divided into two blocks, a linear function applicable to the respective blocks is calculated to obtain two types of linear functions, and the risk of developing an allergy is predicted based on which block an infant belongs to.
Claims3
A method for reducing a risk of developing an allergy to an allergen in infancy, of a 6-month old or younger infant, the method comprising the following steps (a) to (e):
- (a) quantitatively measuring each of IgG1 and IgE antibody titers against an allergen in a sample collected from an infant;
- (b) creating a scattergram by plotting the IgG1 antibody titer on an X axis and the IgE antibody titer on a Y axis;
- (c) calculating a correlation between the IgG1 antibody titer and the IgE antibody titer by regression analysis into:
- (1) linear function 1 represented by Y1=aX1−b, wherein a>0, b>0;
- and (2) linear function 2 represented by Y2=cX2−d, wherein c>a;
- (d) assigning an infant belonging to linear function 1 as having a low risk of developing an allergy to the allergen and assigning an infant belonging to linear function 2 as having a high risk of developing an allergy to the allergen;
- and
- (e) performing a transdermal administration of steroid to sites where a rash is present in the infant belonging to the linear function 2, having developed eczema up to 6 months and with a high risk of developing an allergy to the allergen, or allowing the infant belonging to linear function 2, having developed eczema up to 6 months old and with a high risk of developing an allergen to the allergen, to have continuous and safe ingestion of antigen.
Dependencies are inferred from the claim text.